{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:19:50Z","timestamp":1775452790826,"version":"3.50.1"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,10,21]],"date-time":"2008-10-21T00:00:00Z","timestamp":1224547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1038\/ncpgasthep1277","type":"journal-article","created":{"date-parts":[[2008,10,21]],"date-time":"2008-10-21T12:27:07Z","timestamp":1224592027000},"page":"682-696","source":"Crossref","is-referenced-by-count":67,"title":["Gastrointestinal complications of oncologic therapy"],"prefix":"10.1038","volume":"5","author":[{"given":"Marta","family":"Davila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S","family":"Bresalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,21]]},"reference":[{"key":"BFncpgasthep1277_CR1","first-page":"1","volume":"53","author":"CA Benson","year":"2004","unstructured":"Benson CA et al. (2004) Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association\/Infectious Disease Society of America. MMWR Recomm Rep 53: 1\u2013112","journal-title":"MMWR Recomm Rep"},{"key":"BFncpgasthep1277_CR2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0016-5085(85)80068-8","volume":"88","author":"GB McDonald","year":"1985","unstructured":"McDonald GB et al. (1985) Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 88: 1111\u20131117","journal-title":"Gastroenterology"},{"key":"BFncpgasthep1277_CR3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1086\/380796","volume":"38","author":"PG Pappas","year":"2004","unstructured":"Pappas PG et al. (2004) Guidelines for the treatment of candidiasis. Clin Infect Dis 38: 161\u2013189","journal-title":"Clin Infect Dis"},{"key":"BFncpgasthep1277_CR4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1086\/514028","volume":"176","author":"CM Wilcox","year":"1997","unstructured":"Wilcox CM et al. (1997) A randomized, double-blind comparison of Itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 176: 227\u2013232","journal-title":"J Infect Dis"},{"key":"BFncpgasthep1277_CR5","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1086\/322653","volume":"33","author":"R Ally","year":"2001","unstructured":"Ally R et al. (2001) A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33: 1447\u20131454","journal-title":"Clin Infect Dis"},{"key":"BFncpgasthep1277_CR6","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","volume":"36","author":"JR Perfect","year":"2003","unstructured":"Perfect JR et al. (2003) Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36: 1122\u20131131","journal-title":"Clin Infect Dis"},{"key":"BFncpgasthep1277_CR7","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01191-9","volume":"113","author":"A Villanueva","year":"2002","unstructured":"Villanueva A et al. (2002) A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 113: 294\u2013299","journal-title":"Am J Med"},{"key":"BFncpgasthep1277_CR8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1086\/423377","volume":"39","author":"N De Wet","year":"2004","unstructured":"De Wet N et al. (2004) A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 39: 842\u2013849","journal-title":"Clin Infect Dis"},{"key":"BFncpgasthep1277_CR9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","volume":"39","author":"DS Krause","year":"2004","unstructured":"Krause DS et al. (2004) A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 39: 770\u2013775","journal-title":"Clin Infect Dis"},{"key":"BFncpgasthep1277_CR10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0016-5085(94)90613-0","volume":"106","author":"PH Baehr","year":"1994","unstructured":"Baehr PH and McDonald GB (1994) Esophageal infections: risk factors, presentation, diagnosis, and treatment. Gastroenterology 106: 509\u2013532","journal-title":"Gastroenterology"},{"key":"BFncpgasthep1277_CR11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0016-5107(91)70862-6","volume":"37","author":"RD McBane","year":"1991","unstructured":"McBane RD and Gross JB Jr (1991) Herpes esophagitis: clinical syndrome, endoscopic appearance, and diagnosis in 23 patients. Gastrointest Endosc 37: 600\u2013603","journal-title":"Gastrointest Endosc"},{"key":"BFncpgasthep1277_CR12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7326\/0003-4819-112-7-505","volume":"112","author":"EC Reed","year":"1990","unstructured":"Reed EC et al. (1990) Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med 112: 505\u2013510","journal-title":"Ann Intern Med"},{"key":"BFncpgasthep1277_CR13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/infdis\/172.3.622","volume":"172","author":"C Blanshard","year":"1995","unstructured":"Blanshard C et al. (1995) Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis 172: 622\u2013628","journal-title":"J Infect Dis"},{"key":"BFncpgasthep1277_CR14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archinte.158.9.957","volume":"158","author":"RJ Whitley","year":"1998","unstructured":"Whitley RJ et al. (1998) Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. Arch Intern Med 158: 957\u2013969","journal-title":"Arch Intern Med"},{"key":"BFncpgasthep1277_CR15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","volume":"71","author":"KK Biron","year":"2006","unstructured":"Biron KK (2006) Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71: 154\u2013163","journal-title":"Antiviral Res"},{"key":"BFncpgasthep1277_CR16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0360-3016(99)00163-7","volume":"45","author":"PD Maguire","year":"1999","unstructured":"Maguire PD et al. (1999) Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 45: 97\u2013103","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFncpgasthep1277_CR17","first-page":"90","volume":"9","author":"H Choy","year":"1999","unstructured":"Choy H et al. (1999) Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 9: 90\u201396","journal-title":"Semin Radiat Oncol"},{"key":"BFncpgasthep1277_CR18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0016-5107(04)01882-6","volume":"60","author":"A Repici","year":"2004","unstructured":"Repici A et al. (2004) Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory benign esophageal strictures. Gastrointest Endosc 60: 513\u2013519","journal-title":"Gastrointest Endosc"},{"key":"BFncpgasthep1277_CR19","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0016-5107(04)02278-3","volume":"60","author":"S Evrard","year":"2004","unstructured":"Evrard S et al. (2004) Self-expanding plastic stents for benign esophageal lesions. Gastrointest Endosc 60: 894\u2013900","journal-title":"Gastrointest Endosc"},{"key":"BFncpgasthep1277_CR20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","volume":"21","author":"CS Fuchs","year":"2003","unstructured":"Fuchs CS et al. (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21: 807\u2013814","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0016-5107(98)70159-2","volume":"48","author":"I Raijman","year":"1998","unstructured":"Raijman I et al. (1998) Palliation of malignant dysphagia and fistulae with coated expandable metal esophageal stents: experience with 101 patients. Gastrointest Endosc 48: 172\u2013179","journal-title":"Gastrointest Endosc"},{"key":"BFncpgasthep1277_CR22","unstructured":"National Cancer Institute Common Toxicity Criteria [ http:\/\/www.ctep.cancer.gov\/forms\/CTCAEv3.pdf\/ ]"},{"key":"BFncpgasthep1277_CR23","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2002.20.6.1491","volume":"20","author":"JA Sloan","year":"2002","unstructured":"Sloan JA et al. (2002) Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20: 1491\u20131498","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s005200050079","volume":"5","author":"S Cascinu","year":"1997","unstructured":"Cascinu S et al. (1997) Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. Support Care Cancer 5: 314\u2013317","journal-title":"Support Care Cancer"},{"key":"BFncpgasthep1277_CR25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1995.13.1.210","volume":"13","author":"D Abigerges","year":"1995","unstructured":"Abigerges D et al. (1995) Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13: 210\u2013221","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905\u2013914","journal-title":"N Engl J Med"},{"key":"BFncpgasthep1277_CR27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJMoa010957","volume":"345","author":"DJ Sargent","year":"2001","unstructured":"Sargent DJ et al. (2001) Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med 345: 144\u2013145","journal-title":"N Engl J Med"},{"key":"BFncpgasthep1277_CR28","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2001.19.18.3801","volume":"19","author":"ML Rothenberg","year":"2001","unstructured":"Rothenberg ML et al. (2001) Mortality associated with irinotecan plus bolus fluorouracil\/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801\u20133807","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR29","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1200\/JCO.2007.15.2090","volume":"26","author":"DG Haller","year":"2008","unstructured":"Haller DG et al. (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26: 2118\u20132123","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR30","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/cncr.23013","volume":"110","author":"JP Kuebler","year":"2007","unstructured":"Kuebler JP et al. (2007) Severe enteropathy among patients with stage II\/III colon cancer treated on a randomized trial of bolus 5-Fluorouracil\/Leucovorin plus or minus Oxaliplatin. Cancer 110: 1945\u20131950","journal-title":"Cancer"},{"key":"BFncpgasthep1277_CR31","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/cncr.20594","volume":"101","author":"T Delaunoit","year":"2004","unstructured":"Delaunoit T et al. (2004) Mortality associated with daily bolus 5-fluorouracil\/leucovorin administered in combination with either irinotecan or oxaliplatin. Cancer 101: 2170\u20132176","journal-title":"Cancer"},{"key":"BFncpgasthep1277_CR32","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","volume":"22","author":"R Perez-Soler","year":"2004","unstructured":"Perez-Soler R et al. (2004) Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J Clin Oncol 22: 3238\u20133247","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","volume":"12","author":"D Strumberg","year":"2007","unstructured":"Strumberg D et al. (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four Phase I trials in patients with advanced refractory solid tumors. Oncologist 12: 426\u2013437","journal-title":"Oncologist"},{"key":"BFncpgasthep1277_CR34","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","volume":"24","author":"HJ Lenz","year":"2006","unstructured":"Lenz HJ et al. (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24: 4914\u20134921","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR35","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1056\/NEJM199408253310803","volume":"331","author":"MJ O'Connell","year":"1994","unstructured":"O'Connell MJ et al. (1994) Improving adjuvant therapy for rectal cancer by combining protracted infusion-fluorouracil with radiation therapy after curative surgery. N Engl J Med 331: 502\u2013507","journal-title":"N Engl J Med"},{"key":"BFncpgasthep1277_CR36","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jnci\/86.6.446","volume":"86","author":"D Abigerges","year":"1994","unstructured":"Abigerges D et al. (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86: 446\u2013449","journal-title":"J Natl Cancer Inst"},{"key":"BFncpgasthep1277_CR37","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","volume":"22","author":"AB Benson","year":"2004","unstructured":"Benson AB et al. (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22: 2918\u20132926","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR38","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.1995.13.1.222","volume":"13","author":"S Wadler","year":"1995","unstructured":"Wadler S et al. (1995) Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 13: 222\u2013226","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s005200000220","volume":"9","author":"V Barbounis","year":"2001","unstructured":"Barbounis V et al. (2001) Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9: 258\u2013260","journal-title":"Support Care Cancer"},{"key":"BFncpgasthep1277_CR40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1056\/NEJM199401273300406","volume":"330","author":"CP Kelly","year":"1994","unstructured":"Kelly CP et al. (1994) Clostridium difficile colitis. N Engl J Med 330: 257\u2013262","journal-title":"N Engl J Med"},{"key":"BFncpgasthep1277_CR41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/clinids\/17.1.109","volume":"17","author":"A Anand","year":"1993","unstructured":"Anand A and Glatt AE (1993) Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 17: 109\u2013113","journal-title":"Clin Infect Dis"},{"key":"BFncpgasthep1277_CR42","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/JCM.30.8.2042-2046.1992","volume":"30","author":"GV Doern","year":"1992","unstructured":"Doern GV et al. (1992) Laboratory diagnosis of Clostridium difficile-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays. J Clin Microbiol 30: 2042\u20132046","journal-title":"J Clin Microbiol"},{"key":"BFncpgasthep1277_CR43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2307\/30141083","volume":"16","author":"DN Gerding","year":"1995","unstructured":"Gerding DN et al. (1995) Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 16: 459\u2013477","journal-title":"Infect Control Hosp Epidemiol"},{"key":"BFncpgasthep1277_CR44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0732-8893(93)90062-C","volume":"17","author":"CC Knapp","year":"1993","unstructured":"Knapp CC et al. (1993) Comparison of vidas Clostridium difficile toxin-A assay and premier C. difficile toxin-A assay to cytotoxin-B tissue culture assay for the detection of toxins of C. difficile. Diagn Microbiol Infect Dis 17: 7\u201312","journal-title":"Diagn Microbiol Infect Dis"},{"key":"BFncpgasthep1277_CR45","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMcp011603","volume":"346","author":"JG Bartlett","year":"2002","unstructured":"Bartlett JG (2002) Antibiotic-associated diarrhea. N Engl J Med 346: 334\u2013349","journal-title":"N Engl J Med"},{"key":"BFncpgasthep1277_CR46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1086\/342334","volume":"35","author":"A Apisarnthanarak","year":"2002","unstructured":"Apisarnthanarak A et al. (2002) Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 35: 690\u2013696","journal-title":"Clin Infect Dis"},{"key":"BFncpgasthep1277_CR47","first-page":"415","volume":"42","author":"DR Urbach","year":"1999","unstructured":"Urbach DR and Rotstein OD (1999) Typhlitis. Can J Surg 42: 415\u2013419","journal-title":"Can J Surg"},{"key":"BFncpgasthep1277_CR48","first-page":"867","volume":"80","author":"FJ Tedesco","year":"1985","unstructured":"Tedesco FJ et al. (1985) Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol 80: 867\u2013868","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep1277_CR49","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/1097-0142(19900215)65:4<1041::AID-CNCR2820650433>3.0.CO;2-A","volume":"65","author":"JA Katz","year":"1990","unstructured":"Katz JA et al. (1990) Typhlitis. An 18-year experience and postmortem review. Cancer 65: 1041\u20131047","journal-title":"Cancer"},{"key":"BFncpgasthep1277_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2005.00442.x","volume":"75","author":"M Gorschl\u00fcter","year":"2005","unstructured":"Gorschl\u00fcter M et al. (2005) Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 75: 1\u201313","journal-title":"Eur J Haematol"},{"key":"BFncpgasthep1277_CR51","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/clinids\/17.3.484","volume":"17","author":"MM Sloas","year":"1993","unstructured":"Sloas MM et al. (1993) Typhlitis in children with cancer: a 30-year experience. Clin Infect Dis 17: 484\u2013490","journal-title":"Clin Infect Dis"},{"key":"BFncpgasthep1277_CR52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/1097-0142(19920101)69:1<17::AID-CNCR2820690106>3.0.CO;2-X","volume":"69","author":"DS Wade","year":"1992","unstructured":"Wade DS et al. (1992) Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer 69: 17\u201323","journal-title":"Cancer"},{"key":"BFncpgasthep1277_CR53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000421-200006000-00021","volume":"23","author":"C Kouroussis","year":"2000","unstructured":"Kouroussis C et al. (2000) Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases. Am J Clin Oncol 23: 309\u2013313","journal-title":"Am J Clin Oncol"},{"key":"BFncpgasthep1277_CR54","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/1097-0142(19860201)57:3<603::AID-CNCR2820570335>3.0.CO;2-K","volume":"57","author":"RC Shamberger","year":"1986","unstructured":"Shamberger RC et al. (1986) The medical and surgical management of typhlitis in children with acute nonlymphocytic (myelogenous) leukemia. Cancer 57: 603\u2013609","journal-title":"Cancer"},{"key":"BFncpgasthep1277_CR55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/hon.2900050308","volume":"5","author":"H Anderson","year":"1987","unstructured":"Anderson H et al. (1987) VAD chemotherapy\u2014toxicity and efficacy\u2014in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol 5: 213\u2013222","journal-title":"Hematol Oncol"},{"key":"BFncpgasthep1277_CR56","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565\u20131571","journal-title":"N Engl J Med"},{"key":"BFncpgasthep1277_CR57","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1111\/j.1572-0241.2005.50613_2.x","volume":"100","author":"LJ Brandt","year":"2005","unstructured":"Brandt LJ et al. (2005) Systematic review of the management of chronic constipation in North America. Am J Gastroenterol 100: S5\u2013S21","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep1277_CR58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1572-0241.2001.03549.x","volume":"96","author":"JM Schwartz","year":"2001","unstructured":"Schwartz JM et al. (2001) Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes and outcome. Am J Gastroenterol 96: 385\u2013393","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep1277_CR59","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V76.3.624.624","volume":"76","author":"DJ Weisdorf","year":"1990","unstructured":"Weisdorf DJ et al. (1990) Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 76: 624\u2013629","journal-title":"Blood"},{"key":"BFncpgasthep1277_CR60","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0046-8177(85)80232-X","volume":"16","author":"DC Snover","year":"1985","unstructured":"Snover DC et al. (1985) A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. Hum Pathol 16: 387\u2013392","journal-title":"Hum Pathol"},{"key":"BFncpgasthep1277_CR61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/jcp.41.2.148","volume":"41","author":"L Sviland","year":"1988","unstructured":"Sviland L et al. (1988) Histologic features of skin and rectal biopsy specimens after autologous and allogeneic bone marrow transplantation. J Clin Pathol 41: 48\u201354","journal-title":"J Clin Pathol"},{"key":"BFncpgasthep1277_CR62","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/0016-5085(94)90542-8","volume":"107","author":"GJ Cox","year":"1994","unstructured":"Cox GJ et al. (1994) Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 107: 1398\u20131407","journal-title":"Gastroenterology"},{"key":"BFncpgasthep1277_CR63","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1055\/s-2007-1005576","volume":"28","author":"JP Terdiman","year":"1996","unstructured":"Terdiman JP et al. (1996) The role of endoscopic evaluation in patients with suspected intestinal graft-versus-host disease after allogeneic bone-marrow transplantation. Endoscopy 28: 680\u2013685","journal-title":"Endoscopy"},{"key":"BFncpgasthep1277_CR64","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1182\/blood.V99.8.3033","volume":"99","author":"M Daneshpouy","year":"2002","unstructured":"Daneshpouy M et al. (2002) Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease. Blood 99: 3033\u20133040","journal-title":"Blood"},{"key":"BFncpgasthep1277_CR65","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.bmt.1701423","volume":"22","author":"S Carlens","year":"1998","unstructured":"Carlens S et al. (1998) Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 22: 755","journal-title":"Bone Marrow Transplant"},{"key":"BFncpgasthep1277_CR66","first-page":"69","volume":"5","author":"K Atkinson","year":"1990","unstructured":"Atkinson K (1990) Chronic graft-versus-host disease. Bone Marrow Transplant 5: 69\u201382","journal-title":"Bone Marrow Transplant"},{"key":"BFncpgasthep1277_CR67","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/bbmt.2003.49999","volume":"9","author":"G Akpek","year":"2003","unstructured":"Akpek G et al. (2003) Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant 9: 46\u201351","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFncpgasthep1277_CR68","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/hep.1840080305","volume":"8","author":"HM Shulman","year":"1988","unstructured":"Shulman HM et al. (1988) A coded histologic study of hepatic graft-versus-host disease after human bone marrow transplantation. Hepatology 8: 463\u2013470","journal-title":"Hepatology"},{"key":"BFncpgasthep1277_CR69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.1840040122","volume":"4","author":"DC Snover","year":"1984","unstructured":"Snover DC et al. (1984) Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 4: 123\u2013130","journal-title":"Hepatology"},{"key":"BFncpgasthep1277_CR70","first-page":"1309","volume":"91","author":"RR Babb","year":"1996","unstructured":"Babb RR (1996) Radiation proctitis: a review. Am J Gastroenterol 91: 1309\u20131311","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep1277_CR71","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.cgh.2006.05.016","volume":"4","author":"EB Keeffe","year":"2006","unstructured":"Keeffe EB et al. (2006) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 4: 936\u2013962","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFncpgasthep1277_CR72","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/bjs.1800840333","volume":"84","author":"AD Stockdale","year":"1997","unstructured":"Stockdale AD and Biswas A (1997) Long-term control of radiation proctitis following treatment with sucralfate enemas. Br J Surg 84: 379","journal-title":"Br J Surg"},{"key":"BFncpgasthep1277_CR73","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/j.1572-0241.1998.00493.x","volume":"93","author":"T Sasai","year":"1998","unstructured":"Sasai T et al. (1998) Treatment of chronic post-radiation proctitis with oral administration of sucralfate. Am J Gastroenterol 93: 1593\u20131595","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep1277_CR74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-8140(01)00430-3","volume":"61","author":"R Mayer","year":"2001","unstructured":"Mayer R et al. (2001) Hyperbaric oxygen\u2014an effective tool to treat radiation morbidity in prostate cancer. Radiother Oncol 61: 151\u2013156","journal-title":"Radiother Oncol"},{"key":"BFncpgasthep1277_CR75","first-page":"1814","volume":"91","author":"R Al-Sabbagh","year":"1996","unstructured":"Al-Sabbagh R et al. (1996) Evaluation of short-chain fatty acid enemas: treatment of radiation proctitis. Am J Gastroenterol 91: 1814\u20131816","journal-title":"Am J Gastroenterol"},{"key":"BFncpgasthep1277_CR76","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0167-8140(95)01565-X","volume":"35","author":"BM Biswal","year":"1995","unstructured":"Biswal BM et al. (1995) Intrarectal formalin application, an effective treatment for grade III haemorrhagic radiation proctitis. Radiother Oncol 35: 212\u2013215","journal-title":"Radiother Oncol"},{"key":"BFncpgasthep1277_CR77","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0016-5107(99)70054-4","volume":"49","author":"AC Fantin","year":"1999","unstructured":"Fantin AC et al. (1999) Argon beam coagulation for treatment of symptomatic radiation-induced proctitis. Gastrointest Endosc 49: 515\u2013518","journal-title":"Gastrointest Endosc"},{"key":"BFncpgasthep1277_CR78","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/BF02234451","volume":"44","author":"JJ Tjandra","year":"2001","unstructured":"Tjandra JJ and Sengupta S (2001) Argon plasma coagulation is an effective treatment for refractory hemorrhagic radiation proctitis. Dis Colon Rectum 44: 1759\u20131765","journal-title":"Dis Colon Rectum"},{"key":"BFncpgasthep1277_CR79","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/BF02234452","volume":"44","author":"S Taieb","year":"2001","unstructured":"Taieb S et al. (2001) Effective use of argon plasma coagulation in the treatment of severe radiation proctitis. Dis Colon Rectum 44: 1766\u20131771","journal-title":"Dis Colon Rectum"},{"key":"BFncpgasthep1277_CR80","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0016-5107(99)70228-2","volume":"50","author":"RA Silva","year":"1999","unstructured":"Silva RA et al. (1999) Argon plasma coagulation therapy for hemorrhagic radiation proctosigmoiditis. Gastrointest Endosc 50: 221\u2013224","journal-title":"Gastrointest Endosc"},{"key":"BFncpgasthep1277_CR81","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/BF02049698","volume":"34","author":"ME Lucarotti","year":"1991","unstructured":"Lucarotti ME et al. (1991) Surgical management of intestinal radiation injury. Dis Colon Rectum 34: 865\u2013869","journal-title":"Dis Colon Rectum"},{"key":"BFncpgasthep1277_CR82","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","volume":"100","author":"AS Lok","year":"1991","unstructured":"Lok AS et al. (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100: 182\u2013188","journal-title":"Gastroenterology"},{"key":"BFncpgasthep1277_CR83","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.1999.17.1.394","volume":"17","author":"R Liang","year":"1999","unstructured":"Liang R et al. (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17: 394\u2013398","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR84","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190701411441","volume":"48","author":"S Aksoy","year":"2007","unstructured":"Aksoy S et al. (2007) Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48: 1307\u20131312","journal-title":"Leuk Lymphoma"},{"key":"BFncpgasthep1277_CR85","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","volume":"62","author":"W Yeo","year":"2000","unstructured":"Yeo W et al. (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62: 299\u2013307","journal-title":"J Med Virol"},{"key":"BFncpgasthep1277_CR86","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/sj.bjc.6601699","volume":"90","author":"W Yeo","year":"2004","unstructured":"Yeo W et al. (2004) Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90: 1306\u20131311","journal-title":"Br J Cancer"},{"key":"BFncpgasthep1277_CR87","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2004.05.161","volume":"22","author":"W Yeo","year":"2004","unstructured":"Yeo W et al. (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22: 927\u2013934","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR88","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1034\/j.1600-0609.2001.067001045.x","volume":"67","author":"T Kawatani","year":"2001","unstructured":"Kawatani T et al. (2001) Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 67: 45\u201350","journal-title":"Eur J Haematol"},{"key":"BFncpgasthep1277_CR89","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJM199510263331706","volume":"333","author":"WM Lee","year":"1995","unstructured":"Lee WM (1995) Drug induced hepatotoxicity. N Engl J Med 333: 1118\u20131127","journal-title":"N Engl J Med"},{"key":"BFncpgasthep1277_CR90","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00007611-198502000-00034","volume":"78","author":"JW Goldberg","year":"1985","unstructured":"Goldberg JW and Lidsky MD (1985) Cyclophosphamide-associated hepatotoxicity. South Med J 78: 222\u2013223","journal-title":"South Med J"},{"key":"BFncpgasthep1277_CR91","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/1097-0142(19841201)54:11<2360::AID-CNCR2820541109>3.0.CO;2-D","volume":"54","author":"CB George","year":"1984","unstructured":"George CB et al. (1984) Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer 54: 2360\u20132362","journal-title":"Cancer"},{"key":"BFncpgasthep1277_CR92","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.1993.11.12.2386","volume":"11","author":"CG Moertel","year":"1993","unstructured":"Moertel CG et al. (1993) Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 11: 2386\u20132390","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR93","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.1989.7.11.1646","volume":"7","author":"D Hohn","year":"1989","unstructured":"Hohn D et al. (1989) A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7: 1646\u20131654","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR94","doi-asserted-by":"crossref","first-page":"459","DOI":"10.7326\/0003-4819-107-4-459","volume":"107","author":"N Kemeny","year":"1987","unstructured":"Kemeny N et al. (1987) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 107: 459\u2013465","journal-title":"Ann Intern Med"},{"key":"BFncpgasthep1277_CR95","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00000658-198712000-00001","volume":"206","author":"AE Chang","year":"1987","unstructured":"Chang AE et al. (1987) A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206: 685\u2013693","journal-title":"Ann Surg"},{"key":"BFncpgasthep1277_CR96","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archinte.1968.00300060056011","volume":"122","author":"J Shorey","year":"1968","unstructured":"Shorey J et al. (1968) Hepatotoxicity of mercaptopurine. Arch Intern Med 122: 54\u201358","journal-title":"Arch Intern Med"},{"key":"BFncpgasthep1277_CR97","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1155\/1998\/294752","volume":"12","author":"J Romagnuolo","year":"1998","unstructured":"Romagnuolo J et al. (1998) Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 12: 479\u2013483","journal-title":"Can J Gastroenterol"},{"key":"BFncpgasthep1277_CR98","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0090-8258(86)90123-X","volume":"23","author":"RS Berkowitz","year":"1986","unstructured":"Berkowitz RS et al. (1986) Ten year's experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 23: 111\u2013118","journal-title":"Gynecol Oncol"},{"key":"BFncpgasthep1277_CR99","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0190-9622(82)80064-9","volume":"6","author":"HH Roenigk","year":"1982","unstructured":"Roenigk HH et al. (1982) Methotrexate guidelines: revised. J Am Acad Dermatol 6: 145\u2013155","journal-title":"J Am Acad Dermatol"},{"key":"BFncpgasthep1277_CR100","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/bjc.1992.158","volume":"65","author":"PJ Johnson","year":"1992","unstructured":"Johnson PJ et al. (1992) Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 65: 751\u2013755","journal-title":"Br J Cancer"},{"key":"BFncpgasthep1277_CR101","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jamcollsurg.2005.01.024","volume":"200","author":"FG Fernandez","year":"2005","unstructured":"Fernandez FG et al. (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200: 845\u2013853","journal-title":"J Am Coll Surg"},{"key":"BFncpgasthep1277_CR102","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","volume":"15","author":"L Rubbia-Brandt","year":"2004","unstructured":"Rubbia-Brandt L et al. (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15: 460\u2013466","journal-title":"Ann Oncol"},{"key":"BFncpgasthep1277_CR103","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","volume":"24","author":"JN Vauthey","year":"2006","unstructured":"Vauthey JN et al. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24: 2065\u20132072","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR104","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1478-3231.2007.01511.x","volume":"27","author":"C Hubert","year":"2007","unstructured":"Hubert C et al. (2007) Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases. Liver Int 27: 938\u2013943","journal-title":"Liver Int"},{"key":"BFncpgasthep1277_CR105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jso.2930270415","volume":"27","author":"C Erichsen","year":"1984","unstructured":"Erichsen C and Jonsson PE (1984) Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. J Surg Oncol 27: 268\u2013270","journal-title":"J Surg Oncol"},{"key":"BFncpgasthep1277_CR106","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2141.2003.04578.x","volume":"123","author":"S Stoneham","year":"2003","unstructured":"Stoneham S et al. (2003) Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 123: 100\u2013102","journal-title":"Br J Haematol"},{"key":"BFncpgasthep1277_CR107","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7326\/0003-4819-104-5-651","volume":"104","author":"AE Read","year":"1986","unstructured":"Read AE et al. (1986) Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 104: 651\u2013655","journal-title":"Ann Intern Med"},{"key":"BFncpgasthep1277_CR108","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/hep.1840140511","volume":"14","author":"M Sterneck","year":"1991","unstructured":"Sterneck M et al. (1991) Azathioprine hepatotoxicity after liver transplantation. Hepatology 14: 806\u2013810","journal-title":"Hepatology"},{"key":"BFncpgasthep1277_CR109","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(86)90266-4","volume":"81","author":"BJ Rollins","year":"1986","unstructured":"Rollins BJ (1986) Hepatic veno-occlusive disease. Am J Med 81: 297\u2013306","journal-title":"Am J Med"},{"key":"BFncpgasthep1277_CR110","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-112-11-881_1","volume":"112","author":"G Vassal","year":"1990","unstructured":"Vassal G et al. (1990) Busulfan and veno-occlusive disease of the liver. Ann Intern Med 112: 881","journal-title":"Ann Intern Med"},{"key":"BFncpgasthep1277_CR111","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/1097-0142(19861001)58:7<1437::AID-CNCR2820580710>3.0.CO;2-A","volume":"58","author":"H Joensuu","year":"1986","unstructured":"Joensuu H et al. (1986) Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report. Cancer 58: 1437\u20131440","journal-title":"Cancer"},{"key":"BFncpgasthep1277_CR112","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","volume":"358","author":"PJ Hesketh","year":"2008","unstructured":"Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358: 2482\u20132494","journal-title":"N Engl J Med"},{"key":"BFncpgasthep1277_CR113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000088481","volume":"69","author":"MS Gordon","year":"2005","unstructured":"Gordon MS and Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69: 25\u201333","journal-title":"Oncology"},{"key":"BFncpgasthep1277_CR114","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335\u20132342","journal-title":"N Engl J Med"},{"key":"BFncpgasthep1277_CR115","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/annonc\/mdm508","volume":"19","author":"BD Badgwell","year":"2008","unstructured":"Badgwell BD et al. (2008) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19: 577\u2013582","journal-title":"Ann Oncol"},{"key":"BFncpgasthep1277_CR116","doi-asserted-by":"crossref","first-page":"154s","DOI":"10.1200\/jco.2006.24.18_suppl.3535","volume":"24","author":"M Sugrue","year":"2006","unstructured":"Sugrue M et al. (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 24: 154s","journal-title":"J Clin Oncol"},{"key":"BFncpgasthep1277_CR117","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00006676-199607000-00014","volume":"13","author":"M Runzi","year":"1996","unstructured":"Runzi M and Layer P (1996) Drug-associated pancreatitis: facts and fiction. Pancreas 13: 100\u2013109","journal-title":"Pancreas"},{"key":"BFncpgasthep1277_CR118","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.1996.tb00174.x","volume":"10","author":"KE McArthur","year":"1996","unstructured":"McArthur KE (1996) Review article: drug-induced pancreatitis. Aliment Pharmacol Ther 10: 23\u201328","journal-title":"Aliment Pharmacol Ther"},{"key":"BFncpgasthep1277_CR119","first-page":"59","volume":"123","author":"CJ Glueck","year":"1994","unstructured":"Glueck CJ et al. (1994) Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemia women. J Lab Clin Med 123: 59\u201364","journal-title":"J Lab Clin Med"},{"key":"BFncpgasthep1277_CR120","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1210\/jcem.83.5.4753","volume":"83","author":"Y Hozumi","year":"1998","unstructured":"Hozumi Y et al. (1998) Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 83: 1633\u20131635","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpgasthep1277_CR121","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM197308162890708","volume":"289","author":"H Kawanishi","year":"1973","unstructured":"Kawanishi H et al. (1973) Azathioprine-induced acute pancreatitis. N Engl J Med 289: 357","journal-title":"N Engl J Med"},{"key":"BFncpgasthep1277_CR122","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/1097-0142(19940901)74:5<1627::AID-CNCR2820740522>3.0.CO;2-U","volume":"74","author":"S Izraeli","year":"1994","unstructured":"Izraeli S et al. (1994) Acute pancreatitis after ifosfamide therapy. Cancer 74: 1627\u20131628","journal-title":"Cancer"},{"key":"BFncpgasthep1277_CR123","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0016-5085(80)90689-7","volume":"78","author":"A Mallory","year":"1980","unstructured":"Mallory A and Kern F (1980) Drug-induced pancreatitis: a critical review. Gastroenterology 78: 813\u2013820","journal-title":"Gastroenterology"},{"key":"BFncpgasthep1277_CR124","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/1097-0142(19851015)56:8<1940::AID-CNCR2820560808>3.0.CO;2-N","volume":"56","author":"RF Siemers","year":"1985","unstructured":"Siemers RF et al. (1985) High-dose cytosine arabinoside-associated pancreatitis. Cancer 56: 1940\u20131942","journal-title":"Cancer"},{"key":"BFncpgasthep1277_CR125","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3816\/SCT.2007.n.014","volume":"4","author":"AW Beaven","year":"2007","unstructured":"Beaven AW and Shea TC (2007) The effect of palifermin on chemotherapy and radiation-induced mucositis:a review of the current literature. Support Cancer Ther 4: 188\u2013197","journal-title":"Support Cancer Ther"}],"container-title":["Nature Clinical Practice Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep1277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep1277","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpgasthep1277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:09:51Z","timestamp":1684440591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpgasthep1277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,21]]},"references-count":125,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["BFncpgasthep1277"],"URL":"https:\/\/doi.org\/10.1038\/ncpgasthep1277","relation":{},"ISSN":["1743-4378","1743-4386"],"issn-type":[{"value":"1743-4378","type":"print"},{"value":"1743-4386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,21]]}}}